title: [Comparison of the clinical performance of the ECLusys HBsAg II assay with the Lumipulse f and HISCL 2000-i HBsAg screening assays].
abstract: We compared the ECLusys HBsAgII (ECL HBsAg) assay to the Lumipulse Forte (LPf HBsAg) and HISCL (HIS HBsAg) assays. Measurement of dilution panels for which the WHO HBsAg international reference panel was the parent specimen revealed that the ECL and HIS assays enabled detection to a theoretical level of 0.04 IU/mL, whereas the LPf assay enabled detection to a level of 0.08 IU/mL. In a specificity test using high RF positive specimens (n = 33), pregnancy specimens (n = 35), cytomegalovirus antibody positive specimens (n = 36), and high M protein positive specimens (n = 21) that were confirmed negative for HBsAg by the LPf assay, negative results were obtained for all specimens on the HIS assay, but the ECL assay yielded a positive result for one of the high RF positive specimens. This individual was suggested on further testing to be an HBV carrier who was strongly positive for HBc antibody. In HBsAg mutants detection test, the detection rate was 92.3% with the ECL assay and 69.2% with the HIS assay. In a correlation test using routinely collected clinical specimens (n = 155), including positive stock specimens, aside from the one case where the LPf assay gave a negative result but both the ECL and HIS assays gave positive results, all of the results were consistent for all specimens. The above results confirmed that the ECL assay is both highly sensitive and specific, and also enables a high rate of HBsAg mutant detection.
authors.affiliation: Department of Laboratory Medicine, Hamamatsu University School of Medicine, Hamamatsu 431-3192, Japan.
authors.forename: Aya
authors.initials: A
authors.lastname: Sugiura
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Iwahara
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Suga
authors.forename: Sachinori
authors.initials: S
authors.lastname: Uchiyama
authors.forename: Masato
authors.initials: M
authors.lastname: Maekawa
mesh_terms: D000208:Acute Disease; D015415:Biomarkers / Q000097:blood; D019411:Clinical Laboratory Techniques / Q000379:methods*; D006509:Hepatitis B / Q000175:diagnosis*; D006514:Hepatitis B Surface Antigens / Q000097:blood* / Q000235:genetics; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D006801:Humans; D007118:Immunoassay / Q000379:methods*; D008403:Mass Screening; D009154:Mutation; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity
chemical_list: D015415:Biomarkers; D006514:Hepatitis B Surface Antigens; D011933:Reagent Kits, Diagnostic